Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
▴ Perospirone is an atypical antipsychotic agent for the treatment of schizophrenia. Its primary mode of action is through antagonism of serotonin 5-HT2A and dopamine D2 receptors.
▴ An 8-week course of oral perospirone 8 to 48 mg/day displayed efficacy in up to 75% of patients with schizophrenia participating in phase II and phase III trials. The onset of action of the drug was about 2 weeks.
▴ Perospirone was effective against positive, negative and general symptoms in patients with schizophrenia, as assessed with standard rating scales (Brief Psychiatric Rating Scale, Positive and Negative Symptom Scale).
▴ Compared with haloperidol 2 to 12 mg/day, perospirone 8 to 48 mg/day was significantly more effective against negative symptoms and tended to be more effective against general symptoms and most positive symptoms in a trial in 145 patients with schizophrenia. Perospirone had efficacy similar to that of mosapramine 50 to 300 mg/day in a comparative phase III trial in 159 patients.
▴ Extrapyramidal symptoms (EPS) tended to occur less often and were generally milder with perospirone than with haloperidol or mosapramine.
- Lehman AF. Managing schizophrenia: interventions and outcomes. Dis Manage Health Outcomes 1997 Jun; 1: 286–95 CrossRef
- Emsley RA. Role of newer atypical antipsychotics in the management of treatment-resistant schizophrenia. CNS Drugs 2000; 13(6): 409–20 CrossRef
- Matsubara R, Hirabayashi Y, Narita H, et al. Clinical evaluation of perospirone hydrochloride (SM-9018) in fine granule form in the treatment of schizophrenic patients [abstract]. Int J Neuropsychopharmacol 2000 Jul; 3 Suppl. 1: 139
- Schotte A, Bonaventura P, Janssen PFM, et al. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol 1995 Dec; 69: 399–412 CrossRef
- Hirose A, Kato T, Ohno Y, et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990 Jul; 53: 321–9 CrossRef
- Tojima R, Ohno Y, Ishibashi T, et al. Effects of perospirone (SM-9018), a novel 5-HT2 and D2 antagonist, on human D2 and D4 receptors in CHO cells [abstract]. Jpn J Pharmacol 1997; 73 Suppl. I: 176
- Ohno Y, Ishida-Tokuda K, Ishibashi T, et al. Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity. Pharmacol Biochem Behav 1997 Aug; 57: 889–95 CrossRef
- Ohno Y, Ishibashi T, Okada K, et al. Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats. Prog Neuropsychopharmacol Biol Psychiatry 1995 Oct; 19: 1091–101 CrossRef
- Kusumi I, Takahashi Y, Suzuki K, et al. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm 2000; 107: 295–302 CrossRef
- Ohno Y, Ishida K, Ishibashi T, et al. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats. Gen Pharmacol 1995 May; 26: 489–94 CrossRef
- Ohno Y, Ishida K, Ikeda K, et al. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 1994 Sep; 49: 19–23 CrossRef
- Saito A, Nishimura T, Fukushima M, et al. Pharmaco-EEG study of SM-9018, a D2 and 5-HT2 antagonist in healthy volunteers [abstract]. Psychiatry Res Neuroimaging 1997 Feb 7; 68: 173–4 CrossRef
- Inanaga K, Irie S, Urae A, et al. Phase I study of perospirone HCl (SM-9018) [in Japanese]. Kiso to Rinsho 1997; 31(6): 2113–57
- Mizuno Y, Kanamaru H, Nakatsuka I, et al. Effect of food on the disposition of SM-9018 in cynomolgus monkeys [in Japanese]. Kiso to Rinsho 1997; 31(2): 821–51
- Mizuno Y et al. Disposition of SM-9018 after single oral administration to rats and protein binding to serum of human and animals [in Japanese]. Kiso to Rinsho 1997; 31(2): 543–68
- Mizuno Y, Kanamaru H, Nakatsuka I, et al. Transfer of SM-9018 to fetus and milk in rats [in Japanese]. Kiso to Rinsho 1997; 31(2): 755–88
- Ishibashi T, Ohno Y, Tokuda Y, et al. CNS pharmacological actions of the major metabolites of perospirone hydrochloride [in Japanese]. Kiso to Rinsho 1997; 31(2): 893–902
- Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol [in Japanese]. Rinsho Hyoka 1997; 24(2–3): 159–205
- Kudo Y, Nakajima T, Saito M, et al. Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl on schizophrenia: a comparative double-blind study with mosapramine HCl [in Japanese]. Rinsho Hyoka 1997; 24(2–3): 207–48
- Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: late-phase II study [in Japanese]. Rinsho Hyoka 1997; 31(6): 2181–206
- Murasaki M, Yamashita I, Machiyama Y, et al. Early phase 2 study of a new antipsychotic, perospirone HCl (SM-9018), on schizophrenia [in Japanese]. Kiso to Rinsho 1997; 31(6): 2159–79
- Murasaki M, Koyama T, Machiyama Y, et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a study of long-term administration [in Japanese]. Kiso to Rinsho 1997; 31(6): 2207–30
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987
- World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death, 9th revision. v. l. Grneva: WHO, 1977
- World Health Organization. International statistical classification of diseases and related health problems, 10th revision. v. 1. Geneva: WHO, 1992
- Lader M. Rating scales in schizophrenia: a review of their usefulness for assessing atypical antipsychotics. CNS Drugs 2000; 14(1): 23–32 CrossRef
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261–76 CrossRef
Volume 15, Issue 4 , pp 329-337
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links